Here are the 10-K annual reports from CryoPort, Inc. (CYRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CYRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYRX filings page.
Cryoport, Inc. files its annual report describing a focused strategy as a global provider of temperature-controlled supply chain solutions for life sciences, with emphasis on the fast‑growing cell and gene therapy market. As of December 31, 2025, the company supported 760 clinical trials and 20 commercially approved cell and gene therapies.
Cryoport reports two segments: Life Sciences Services, which generated 54.8% of 2025 revenue through BioLogistics, BioStorage, BioServices and cryopreservation offerings, and Life Sciences Products, where cryogenic systems manufacturing contributed 45.2%. Revenue is concentrated in the Americas, which accounted for 74.5% of 2025 sales, with EMEA at 14.3% and APAC at 11.2%.
In 2025 Cryoport completed the divestiture of its CRYOPDP specialty courier business to DHL affiliates for $133.0 million, plus repayment of approximately $77.2 million of intercompany loans, and entered a master partnership aimed at strengthening presence in EMEA and APAC. One Life Sciences Services customer represented 10.2% of 2025 revenue, highlighting some customer concentration risk.
The report details heavy investment in digital platforms (Cryoportal, Smartpak, Tec4med IoT, the planned MVE CryoVerse ecosystem) and quality frameworks like Chain of Compliance and multiple ISO and GMP certifications. It also outlines extensive risk factors, including supply chain dependence on key components, product liability (particularly in reproductive medicine and biostorage), foreign currency exposure, cyber‑security threats, regulatory complexity and potential goodwill and intangible asset impairments.